Molecular & Genetic Markers
BRAF V600E mutation
A BRAF V600E mutation is a growth-pathway change found in some gliomas — particularly certain pediatric ones — that can be targeted by specific drugs.
In short: BRAF V600E mutation
- It is a specific mutation in the BRAF gene.
- It activates a growth-signaling (MAPK) pathway.
- It is found in some gliomas, particularly certain pediatric types.
- It can be targeted by BRAF inhibitor drugs.
What it is
A BRAF V600E mutation is a specific change in the BRAF gene that activates a growth-signaling pathway (the MAPK pathway), driving tumor growth. It is found in some gliomas — particularly certain pediatric low-grade gliomas and some other tumor types — and importantly, it can be targeted by specific drugs.
Understanding BRAF V600E mutation
The BRAF gene is part of the MAPK/ERK signaling pathway, which controls cell growth. The V600E mutation locks BRAF in an "on" state, continuously signaling cells to grow. This mutation appears in various gliomas, including some pleomorphic xanthoastrocytomas, gangliogliomas, pilocytic astrocytomas, and a portion of pediatric (and some adult) high-grade gliomas. Its great practical importance is that drugs called BRAF inhibitors (often combined with MEK inhibitors) specifically target BRAF V600E-mutant tumors and can be effective, offering a targeted treatment option. Testing for BRAF V600E is therefore valuable, especially in pediatric gliomas. Understanding the BRAF V600E mutation clarifies a targetable growth-pathway change found in some gliomas.
Why it matters
Understanding the BRAF V600E mutation helps patients and families see a targetable change found in some gliomas — its presence opens the option of BRAF inhibitor drugs, which can be effective, especially in certain pediatric tumors.
Common questions
What is a BRAF V600E mutation?
A change in the BRAF gene that activates a growth pathway.
Where is it found?
In some gliomas, particularly certain pediatric types.
Can it be targeted?
Yes — by BRAF inhibitor drugs.
Bottom line
A BRAF V600E mutation activates a growth pathway in some gliomas — particularly certain pediatric ones — and can be targeted by BRAF inhibitor drugs.
Browse all 265 Glioma definitions
Read the Glioma patient guides
Not sure which page you need? Put words to it with the symptom navigator